Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

DNA Immunization for HIV Vaccine Development.

Chen Y, Wang S, Lu S.

Vaccines (Basel). 2014 Feb 25;2(1):138-59. doi: 10.3390/vaccines2010138. Review.

2.

Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.

Bowles EJ, Schiffner T, Rosario M, Needham GA, Ramaswamy M, McGouran J, Kessler B, LaBranche C, McMichael AJ, Montefiori D, Sattentau QJ, Hanke T, Stewart-Jones GB.

PLoS One. 2014 Dec 9;9(12):e114709. doi: 10.1371/journal.pone.0114709. eCollection 2014.

3.

A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Jones B, Surman S, Sealy R, Freiden P, Branum K, Slobod KS.

J Pediatr Pharmacol Ther. 2007 Apr;12(2):68-76. doi: 10.5863/1551-6776-12.2.68.

4.

UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Jones BG, Sealy RE, Zhan X, Freiden PJ, Surman SL, Blanchard JL, Hurwitz JL.

Vaccine. 2012 May 2;30(21):3188-95. doi: 10.1016/j.vaccine.2012.03.001. Epub 2012 Mar 14.

5.

Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Powell RL, Kinge T, Nyambi PN.

J Virol. 2010 Sep;84(18):9415-26. doi: 10.1128/JVI.02732-09. Epub 2010 Jul 14.

6.

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL.

Viruses. 2010 Feb 1;2(2):435-467.

7.

HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen.

Surman SL, Sealy R, Jones BG, Hurwitz JL.

Hum Vaccin. 2009 Apr;5(4):268-71. Review.

8.

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Sealy R, Slobod KS, Flynn P, Branum K, Surman S, Jones B, Freiden P, Lockey T, Howlett N, Hurwitz JL.

Int Rev Immunol. 2009;28(1):49-68. doi: 10.1080/08830180802495605. Review.

9.

A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

Huber VC, Thomas PG, McCullers JA.

Vaccine. 2009 Feb 18;27(8):1192-200. doi: 10.1016/j.vaccine.2008.12.023. Epub 2009 Jan 7.

10.

Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.

Seaman MS, Leblanc DF, Grandpre LE, Bartman MT, Montefiori DC, Letvin NL, Mascola JR.

Virology. 2007 Oct 10;367(1):175-86. Epub 2007 Jun 27.

11.

A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho Z, Ma BJ, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF.

Virology. 2006 Sep 30;353(2):268-82.

12.

Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Slobod KS, Coleclough C, Brown SA, Stambas J, Zhan X, Surman S, Jones BG, Zirkel A, Freiden PJ, Brown B, Sealy R, Bonsignori M, Hurwitz JL.

AIDS Res Ther. 2005 Apr 28;2(1):3.

Supplemental Content

Support Center